

**PABST PATENT  
GROUP****RECEIVED  
CENTRAL FAX CENTER****SEP 14 2004**

Pabst Patent Group LLP  
400 Colony Square, Suite  
1200  
1201 Peachtree Street  
Atlanta, GA 30361

Telephone (404) 879-2150  
Telefax (404) 879-2160

information@pabstpatent.com  
www.pabstpatent.com

**TELEFAX****Date:** September 14, 2004**Total pages:** 31 (Inc. Fax  
Cover)**To:** US PTO**Telephone:** 571-272-0861**Telefax:** 703-872-9306**From:** Patrea L. Pabst**Telephone:** 404-879-2151**Telefax:** 404-879-2160**Our Docket No.** CP 101 CIP CON  
**Your Docket No.****Client/Matter No.** 085337/0004

Please call (404) 879-2150 if you did not receive all of the pages, or if they are illegible.

**CONFIDENTIALITY NOTICE:** This facsimile, along with any documents, files, or attachments, may contain information that is confidential, privileged, or otherwise exempt from disclosure. If you are not the intended recipient or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, printing, distribution or use of any information contained in or attached to this facsimile is strictly prohibited. If you have received this facsimile in error, please immediately notify us by facsimile or by telephone collect at the numbers stated above, and destroy the original facsimile and its attachments without reading, printing, or saving in any manner. Your cooperation is appreciated. Thank you.

**MESSAGE:****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Applicant:** Saul Tzipori, Ramaswamy Balakrishnan and Arthur Donohue-Rolfe**Serial No.:** 10/041,958**Art Unit:** 1645**Filed:** January 7, 2002**Examiner:** Albert Mark Navarro**For:** *HUMAN NEUTRALIZING ANTIBODIES AGAINST HEMOLYTIC UREMIC  
SYNDROME*

{45050710.1}


SEP 14 2004


PTO/SB/21 (08-03)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/041,958	
	Filing Date	January 7, 2002	
	First Named Inventor	Saul Tzlpori	
	Art Unit	1645	
	Examiner Name	Navarro, Albert Mark	
Total Number of Pages in This Submission	31	Attorney Docket Number	CP 101 CIP CON

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input checked="" type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Patricia L. Pabst, Esq., Reg. No. 31,284 Pabst Patent Group LLP 400 Colony Square, Suite 1200, Atlanta, GA 30361	
Signature		
Date	September 14, 2004	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Chandra Russell		
Signature		Date	September 14, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

CP 101 CIP CON 085337/4

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 165.00)

## Complete if Known

Application Number	10/041,958
Filing Date	January 7, 2002
First Named Inventor	Saul Tzipori
Examiner Name	Navarro, Albert Mark
Art Unit	1645
Attorney Docket No.	CP 101 CIP CON

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None
☒ Deposit Account:
 Deposit  
Account  
Number  
Deposit  
Account  
Name

50-3129

Pabst Patent Group LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

## 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 590	2003 285	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	

SUBTOTAL (1) (\$ 0)

## 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
11	-20*	0	0
1	-3**	0	0
Multiple Dependent		0	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 280	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0.00)

\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

## 3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	165.00
1403 280	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1808 160	1808 160	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 165.00)

## SUBMITTED BY

Name (Print/Type) Patrea L. Pabst

Signature

Registration No.  
(Attorney/Agent)

31,284

(Complete if applicable)

Telephone (404) 879-2151

Date

September 14, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CP 101 CIP CON 085337/4

If you need assistance in completing this form, call 1-800-PTO-0100 and select option 2.

SEP 14 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Saul Tzipori, Ramaswamy Balakrishnan and Arthur Donohue-Rolfe

Serial No.: 10/041,958

Art Unit: 1645

Filed: January 7, 2002

Examiner: Mark Navarro

For: *HUMAN NEUTRALIZING ANTIBODIES AGAINST HEMOLYTIC  
UREMIC SYNDROME*

Box Appeal Stop  
Commissioner for Patents  
Washington, D. C. 20231

**APPEAL BRIEF**

Sir:

This is an appeal from the rejection of claims 26-36 in the Office Action mailed April 16, 2004, in the above-identified patent application. A Notice of Appeal was filed on July 16, 2004. The Commissioner is hereby authorized to charge the fee in the amount of \$165.00, for the filing of this Appellants' Brief, to Deposit Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 50-3129.

**(1) REAL PARTY IN INTEREST**

The real party in interest of this application is the assignee, Trustees of Tufts College, Medford, MA.

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

**(2) RELATED APPEALS AND INTERFERENCES**

There is a related appeal in Serial No: 10/230,614 filed August 29, 2002, which directly affects, which would be directly affected by, or which may have a bearing on the Board's decision in this appeal.

**(3) STATUS OF CLAIMS ON APPEAL**

Claims 26-36 are pending and on appeal. The text of each claim on appeal, as amended, is set forth in the Appendix to this Appeal Brief.

**(4) STATUS OF AMENDMENTS**

The pending claims were last amended by the Amendment mailed January 9, 2004, and entered upon filing of a Request for Continued Examination filed February 4, 2004.

**(5) SUMMARY OF THE INVENTION**

Appellants have developed a dosage formulation to prevent or treat hemolytic uremic syndrome in a human individual exposed to or infected by *Escherichia coli* producing Shiga-like toxin II, which can be administered by administering intradermally, subcutaneously, intravenously, or intramuscularly, to an individual presenting with bloody diarrhea, diagnosed with infection by *Escherichia coli* producing Shiga-like toxin II, or exposed to an individual infected with or exposed to the same source of infection with *Escherichia coli* producing Shiga-like toxin II, comprising an effective amount of monoclonal human or humanized antibodies consisting of antibodies neutralizing Shiga like toxin II, to prevent or treat hemolytic uremic syndrome in a human (page 5, line 4- page 6, line 11; page 7, lines 10-22; claim 26). In the preferred embodiment, the monoclonal antibodies are human monoclonal antibodies or produced by recombinant

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

DNA methodology, for example, chimeric monoclonal antibodies (page 12, line 18, to page 15, line 24; examples; claims 27-29).

In one embodiment, the antibodies are administered when the individual presents with bloody diarrhea (page 8, line 25, to page 9, line 4). Alternatively, the antibodies are administered to the individual prior to the onset of symptoms (page 8, lines 16-24, such as bloody diarrhea, cerebral hemorrhage, seizures, or kidney damage. In other embodiments, the antibodies are administered when the individual is diagnosed with *E. coli* infection, or at the onset of hemolytic uremic syndrome (page 20, lines 5-16).

The claims in this appeal are specific to the dosage formulation per se, and are drawn to antibodies to specific subunits (page 7, lines 10-18; pages 16-60, especially pages 44-45; claims 30 and 33) and specific dosages (claims 34-36) which could be determined only by the use of an animal model that was actually predictive of human infection (the neonatal pig) using bacterial strains obtained from humans with severe disease that at least in some cases was fatal (examples at pages 16-60).

#### (6) ISSUES ON APPEAL

The issue presented on appeal is whether claims 26-36 are obvious under 35 U.S.C. 103 over U.S. Patent No. 5,512,28 to Krivan *et al.* ("Krivan") and Perera, *et al.*, J. Clin. Microbiol. 26(10), 2127-2131 (1988) in view of WO 90/07861 by Queen *et al.* and Engelman *et al.*, Human Hybridomas and Monoclonal Antibodies, NY Plenum Press 1985 pp. 23-27 ("Engelman") and further in view of U.S. Patent No. 6,080,400 to Williams.

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

## (7) GROUPING OF CLAIMS

The claims do not stand or fall together, as discussed in more detail below. There are a number of elements not disclosed by the prior art, in addition to the failure to provide the motivation to select and combine the elements as defined by the independent claims.

Claims 27-29 are drawn to the source of the monoclonal antibodies (claim 27, human; claim 28, recombinant DNA; claim 29, chimeric antibodies).

Claims 30 and 33 are specific to particular subunits of the Shiga like toxin II.

Claim 31 is drawn to a specific formulation for preventing the neurological signs of HUS - none of the prior art even recognizes this is an issue, much less provides guidance on what would be an effective amount to treat or prevent.

Claims 32, and 34- 36 relate to specific dosages. There is no art even remotely disclosing the effective dosages.

## (8) ARGUMENTS

### (a) The Invention

Hemolytic uremic syndrome, or HUS, is a disorder marked by kidney failure, hemolytic anemia, thrombocytopenia (platelet deficiency), coagulation defects, and variable nervous system signs. This disorder is most common in children. It frequently occurs after a gastrointestinal (enteric) infection, often one caused by a specific *E. coli* bacteria (*Escherichia coli* O157:H7). It has also been associated with other enteric infections including *Shigella* and *Salmonella* and some non-enteric infections.

HUS, once relatively rare, is increasing in children. It is the most common cause of acute kidney failure in children. Several large outbreaks in 1992 and 1993 were

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

attributed to undercooked hamburger contaminated with *E. coli*. Because of this association, supermarket hamburger has new labeling, and there are new temperature guidelines for hamburger cooked at fast-food chains and restaurants. HUS is less common in adults.

HUS is one of the most common causes of sudden, short-term kidney failure in children. In severe cases, this acute kidney failure may require several sessions of dialysis to take over the kidneys' job of filtering wastes from the blood, but most children recover without permanent damage to their health. Most cases of HUS occur after an infection of the digestive system by *Escherichia coli* bacterium, which is found in contaminated foods like meat, dairy products, and juice. Some people have contracted HUS after swimming in pools or lakes contaminated with feces. The infection of the digestive tract is called gastroenteritis and may cause the child to vomit and have stomach cramps and bloody diarrhea. Most children who experience gastroenteritis recover fully in 2 or 3 days and do not develop HUS. In a few children, however, HUS develops when the bacteria lodged in the digestive system make toxins that enter the bloodstream and start to destroy red blood cells. Symptoms of HUS may not become apparent until a week after the digestive problems. The child remains pale, tired, and irritable. Other symptoms include small, unexplained bruises or bleeding from the nose or mouth that may occur because the toxins also destroy the platelets, cells that normally help clotting. Urine formation slows because the damaged red blood cells clog the tiny blood vessels in the kidneys, making them work harder to remove wastes and extra fluid from the blood. The body's inability to rid itself of excess fluid and wastes may in turn cause high blood pressure or swelling



U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

of the face, hands, feet, or the entire body. This progression to acute kidney failure occurs in about half the cases of HUS.

Bacteria such as *E. coli* vary tremendously in the hosts that they infect and which toxins they produce. Some strains primarily affect cattle, others pigs, still others humans. Results obtained using organisms isolated from humans will be different from results obtained from organisms isolated from cattle or pigs. Only recently has it been known which of the many toxins produced by the various bacteria cause the most serious illness. This is in part due to the lack of an appropriate animal model, discussed below, which could be used to compare the effects of the different toxins, and antibodies specific to the different toxins. Appellants were the first to discover that of the two major toxins produced by *E. coli* implicated in HUS in humans, Shiga-like toxin I and Shiga-like toxin II, it is the latter, Shiga-like toxin II, that causes the worst symptoms of HUS, leading to kidney failure and death. This is important since one can screen bacteria to see which toxins, and in which amounts, are produced. As demonstrated by the examples in appellants' specification, bacteria which produce Shiga-like toxin I ("stx1"), or a mixture of Shiga-like toxin II ("stx2"), are not as deadly as strains that produce primarily Shiga-like toxin II. However, the studies also show that one can administer antibodies directed to the Shiga-like toxin II, rather than a mixture of antibodies, and selectively prevent the worst symptoms of the disease. Since treatment is primarily supportive, the patients will then recover without the permanent kidney damage and other long term side-effects of the disease.

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

**(b) Rejection Under 35 U.S.C. § 103**

Claims 26-36 were rejected under 35 U.S.C. § 103(a) as obvious over U.S. Patent No. 5,512,282 to Krivan *et al.* ("Krivan") and Perera *et al.* J. Clin. Microbiol. 26(10):2127-2131 (1988) ("Perera") in view of WO 90/07861 by Protein Design Labs, Inc ("Queen") and Engelman *et al.* "Human Hybridomas and Monoclonal Antibodies ed. Engleman, Fount, Larrick, Raubitschek (Plenum Press 1985) pp. 95-112 ("Engelman") and further in view of U.S. Patent No. 6,080,400 to Williams.

None of the prior art teaches one skilled in the art to use an antibody to only a single subunit of the Stx2 for treatment or prevention of disease. None of the prior art recognizes that one only has to block Stx2 to prevent the mortality and other extremely serious complications of HUS associated with certain highly virulent strains of *E. coli*. None of the prior art recognizes that the toxins associated with strains of *E. coli* that infect humans, as compared to other animals, are different, and that antibodies to toxin from animal strains may not be effective in treating or preventing complications of HUS. None of the prior art recognizes that one can block only a single subunit and still treat or prevent the high mortality or serious complications of HUS. Without recognizing these aspects, and identifying a useful animal model, one cannot predict an effective dosage, much less the dosage ranges defined by the dependent claims.

As discussed in more detail below, the art recognizes that antibodies should be useful in the treatment of HUS (Krivan, Williams). The art recognizes that one can make antibodies to just one subunit (Perera) which are useful in diagnostics. There is nothing that would lead one to substitute these subunit specific antibodies into Krivan, determine

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

an effective dosage, and then have a reasonable expectation of success. None of the art demonstrates any successful treatment or prevention of clinical symptoms.

Therefore one skilled in the art would not be lead either to select antibodies as defined by all claims now pending, not just claim 30 as previously presented, nor to have a reasonable expectation of success if one did so.

i. *The Legal Standard for Obviousness*

"References relied upon to support a rejection under 35 USC 103 must provide an enabling disclosure, i.e., they must place the claimed invention in the possession of the public." *Application of Payne*, 606 F.2d 303, 314, 203 U.S.P.Q. 245 (C.C.P.A. 1979); *see Beckman Instruments, Inc. v. LKB Produkter AB*, 892 F.2d 1547, 13 U.S.P.Q.2d 1301 (Fed. Cir. 1989). A publication that is insufficient as a matter of law to constitute an enabling reference may still be relied upon, but only for what it discloses. *See Reading & Bates Constr. Co. v. Baker Energy Resources Corp.*, 748 F.2d 645, 651-652, 223 U.S.P.Q. 1168 (Fed. Cir. 1984); *Symbol Technologies, Inc. v. Opticon, Inc.*, 935 F.2d 1569 (Fed. Cir. 1991).

"Focusing on the obviousness of substitutions and differences, instead of on the invention as a whole, is a legally improper way to simplify the often difficult determination of obviousness." *Gillette Co. v. S.C. Johnson & Sons, Inc.*, 919 F.2d 720, 724, 16 U.S.P.Q.2d 1923 (Fed. Cir. 1990); *see Hybritech Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1383, 231 U.S.P.Q. 81, 93 (Fed. Cir. 1986). "One cannot use hindsight reconstruction to pick and choose among isolated disclosures on the prior art to deprecate the claimed invention." *In re Fine*, 837 F.2d 1071, 1075 (Fed. Cir. 1988). The prior art must provide one of ordinary skill in the art with the motivation to make the

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

proposed modifications needed to arrive at the claimed invention. See *In re Geiger*, 815 F.2d 686, 2 U.S.P.Q.2d 1276 (Fed. Cir. 1987); *In re Lahu and Foulletier*, 747 F.2d 703, 705, 223 U.S.P.Q. 1257, 1258 (Fed. Cir. 1984). Claims for an invention are not *prima facie* obvious if the primary references do not suggest all elements of the claimed invention and the prior art does not suggest the modifications that would bring the primary references into conformity with the application claims. *In re Fritch*, 23 U.S.P.Q.2d, 1780 (Fed. Cir. 1992). *In re Laskowski*, 871 F.2d 115 (Fed. Cir. 1989). This is not possible when the claimed invention achieves more than what any or all of the prior art references allegedly suggest, expressly or by reasonable implication. Here, the references do not teach one skilled in the art to select an antibody to a subunit of Stx2, in a therapeutically effective dosage, to treat or prevent HUS.

ii. *The Claimed Invention*

The claims define a formulation containing an effective dosage of antibodies reactive with a single subunit of Shiga toxin II, which neutralize Shiga toxin II, thereby preventing or treating hemolytic uremic syndrome ("HUS") in a human. The effective dosage for humans could be determined only using the neonatal pig model. See the example at pages 19-24. Absent this animal model, which is the only one predictive of human disease, one could not have determined an effective amount, the examiner's unsupported conclusions to the contrary. This is important to all of the claims on appeal, especially those defining a specific dosage, including claims 1 (effective amount), 31 (prevent neurological symptoms of HUS), 32 (prolong survival), and 34-36, which define actual dosages which were empirically determined to be effective.

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

The application demonstrates the efficacy of antibodies immunoreactive with a single subunit in preventing HUS associated mortality. Figures 2 and 3 demonstrate that applicants' humanized antibodies are neutralizing antibodies and their subunit specificity. Figures 4 and 6 show the average survival time of mice exposed to shiga like toxin II ("Stx2"), without treatment, and after treatment with humanized antibodies to subunit A of Stx2 (these results correlate with those in Figure 2, for antibody 5C12, which neutralizes Stx2 and Stx2A, and 6G3, which neutralizes Stx2 and Stx2A, showing that the antibody to the Stx2A is most effective). Sheoran, et al., "Tsx2-specific human monoclonal antibodies protect mice against lethal infection with *E. coli* expressing Stx2 variants" Infect. Innum. 71(6):3125-3130 (June 2003) was submitted as further evidence that the monoclonal antibodies to the individual subunits are protective, but that their activities are different depending on the specificity. As the data in the application and the paper demonstrates, the anti-Stx2 A antibodies have broader protectivity than the anti-Stx2 B antibodies. This is particularly relevant to claims 30 and 33, which are drawn to antibodies to specific subunits.

The prior art fails to teach any guidance as to (1) the selection of antibodies to Shiga toxin II only to treat or prevent HUS, (2) that antibodies to a single subunit of Stx2 can be effective in preventing or treating disease (not just in a diagnostic assay) and (3) what constitutes an effective dosage of these antibodies. It would not have been obvious from studies using animals such as mice what an effective dosage would be, since mice are very resistant to infection, requiring many times more toxin to become sick, than humans. Only pigs have been proven to be a good model for humans (it is the only other animal species that naturally develops systemic complications when infected with Shiga

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

toxin-producing *E. coli*), and therefore a model that allows determination of an effective dosage. Cattle cannot be used as animal models for human disease, since cattle do not contain the receptors on their blood vessels, and therefore are not susceptible to the systemic disease as humans and piglets do. Therefore only studies conducted in pigs or humans can be used to determine the critical components of the disease causing etiological agent, what compounds would be effective to treat these critical components, and what the effective dosage of these compounds would be.

Moreover, the organisms isolated from cattle are antigenically distinct from the organisms isolated from humans. Even the terms are different. For example, the Shiga-like toxin II from *E. coli* infecting cattle is more similar to the Shiga-like toxin I of the *E. coli* infecting humans.

iii. *The Prior Art:*

Krivan

Krivan does not place one of skill in the art with antibodies to STX2 which would be effective to treat or prevent HUS. Krivan only provides animal antibodies, and it is not clear to what toxin - it appears that it is only to the SLT forms that cause animal disease, not to the STX2 form causing HUS. Perera does not teach antibodies for therapeutic use and suggests that antibodies to subunits of Stx2 are not as effective as antibodies to Stx1. An important aspect of the studies conducted by Appellant was the use of a strain of bacteria which *infects and causes disease in humans*. Krivan does not recognize that the strains infect different hosts, and therefore that one cannot extrapolate from reagents in one species, cattle, for use in another, humans, even though the

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

organism, *E. coli*, are the same, since there are differences in the toxins, and in the host species, cattle and humans which are infected differently and have different diseases.

Krivan teaches polyclonal, monospecific *bovine* antibodies for the detection of a Shiga-like toxin or for treating hemolytic uremic syndrome. There is no disclosure or suggestion in this reference to obtain a human monoclonal antibody that will bind to, and specifically neutralize, a Shiga-like toxin II in humans. Moreover, as discussed in Dr. Tzipori's declaration, previously submitted, discussed below, Krivan only teaches oral administration of antibody which would not be effective in treating or preventing human disease due to digestion of the antibody in the human stomach prior to reaching the intestines.

In fact, Krivan says his antibodies and invention *are not, and cannot be, useful in humans*. As the following excerpt from the patent makes clear, the animals to be treated to make antibodies *do not possess receptors for the toxin (thereby excluding humans), and the resulting antibodies therefore would not be administerable to humans (it is well known one cannot administer bovine antibodies to humans)*:

"To achieve the objects and accordance with the purpose of the invention, as embodied and broadly described herein, the present invention provides an antitoxin to one or more SLTs. It comprises purified IgG that contains high titer, monospecific polyclonal antibodies to a Shiga-like toxin. (col. 6, lines 17-21)

The antibodies can be purified from the IgG. Therefore, the invention also provides high titer, monospecific, purified polyclonal antibodies to an SLT. Preferably, the antibodies comprise bovine IgG." (col. 6, lines 22-26)

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

"As used herein, the term "Shiga-like toxin (SLT)" refers to any cytotoxin similar in both structure and function to Shiga toxin. Known SLTs include SLT-I, STX2, and STX2I. They also include known variants of STX2, which are STX2v, STX2vh, and STX2vp. The term encompasses the presently unknown SLTs or variants thereof that may be discovered in the future, since their characterization as an SLT or variant thereof will be readily determinable by persons skilled in the art." (col. 7, line 65 to col. 8, line 6)

"The purified IgG of the invention is made by a novel modification of standard techniques for making polyclonal antibodies by inoculating an animal with an antigen and recovering immunoglobulins from a fluid, such as serum, that contains the immunoglobulins after the animal has had an immune response. The inventors surprisingly and unexpectedly discovered that they were able to inoculate a bovine animal with a purified, preferably active, SLT without significant ill effect to the animal." (page 8, lines 7-15)

"Without wishing to be bound by theory, the inventors hypothesized that the cell membranes of the cells of such an animal do not contain a receptor for SLTs or only contain low levels of receptors, when compared to other mammals or humans. Presumably, this allows high amounts of purified, active toxin to be inoculated into the animal and presumably allows the toxin to remain in unbound form longer in the animal, thereby creating a much greater antigenic response." (col. 8, lines 16-24)

*"Therefore, the method of the invention is applied to any animal that has few or no receptors to SLTs. Such animals can be identified by those skilled in the art through standard techniques involving the injection of an SLT into the animal and the*



U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

*observation of its effect on the animal and the titer of antibodies produced by the animal.* " (emphasis added) (col. 8, lines 25-30)

Accordingly, there is no teaching in Kriven of the need to make human or humanized antibodies to STX2, no teaching of how to make such antibodies, no recognition that this is the critical toxin to protect against, much less what an effective dosage is, and even less so that one might target a specific subunit of the toxin. Polyclonal antibodies would not be specific to a single subunit *unless one actively took the step of removing antibodies from the mixture which are reactive with the other subunit and the combination of subunits.* One skilled in the art would be led away from what applicants' have, from the teaching of Krivan which is to use bovine antibody reactive with multiple epitopes in the toxin, which is administered parenterally.

Williams

It is not clear that Williams is available as prior art, even under 35 U.S.C. 102(e), since it issued on an application filed March 13, 1997, well after appellants' priority date of November 15, 1996. Williams is drawn to the use of *avian* antibodies elicited by immunization of birds with recombinant, preferably cross-linked toxin fragments. These can allegedly be from subunit A or B of the toxin, which can be from a pathogenic strain of *E. coli*, including an *E. coli* which infects humans (col. 17). It is clear there is no stated preference between stx1 and stx2 (col. 20, lines 38-45) although studies in mice showed protection from lethality *only* by using antibody to stx1, even though the antibody was a neutralizing antibody, (col. 66) which is the complete opposite to what appellant claims. From the discussion at col. 24, line 42 to col. 25, line 4, the patentees believed one can only obtain neutralizing antibodies by immunization to both subunits A

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

and B, arranged in a conformationally correct manner. Of course, there studies prove that just because an antibody is a neutralizing antibody, does not mean it protects from the toxin. There is no teaching or even recognition that one cannot inject avian antibodies into humans - see col. 27, line 62 to col. 28, line 44. The only immunization studies performed were in chickens and mice (col. 62-64), neither appropriate animal models for human treatment. The only administration of antibodies was from rabbits into mice (example 19). However, the study was not done as it would occur in a natural state (oral infection) but by premixing toxin and antibody, then injecting it intraperitoneally into the mice. Col. 66.

Perera

Perera is relied upon for its teaching of toxin neutralization. Perera teaches five monoclonal antibodies which bind to the  $\alpha$ -subunit of STX2 and were able to neutralize the toxin as assayed using HeLa cells or Vero cells *in vitro* (for example, see Materials and Methods, page 2128, 2<sup>nd</sup> column). As noted at page 2130, col. 2, the antibodies are useful in diagnostics of disease. There is no mention of therapy other than to note that the shiga like toxins may play a role in disease "although no direct proof for the involvement of SLTs in pathogenesis has yet been demonstrated." Perhaps more importantly, page 2131, col. 1, discusses the relative specificity and sensitivity of the antibodies, and notes that none of the antibodies to the Stx2 only were able to detect organisms; antibodies to Stx2 which were effective were only able to detect organisms producing both Stx1 and Stx2. Accordingly, one would not be led by Perera to use these antibodies in therapy, nor one would have a reasonable expectation of success using just

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

an antibody to Stx2, much less to a single subunit of St2. The diagnostic results here clearly teach away from the use of the anti-Stx2 antibodies.

Perera even in combination with Krivan or Williams does not teach that these monoclonal antibodies alone would be effective in treating or preventing HUS, nor in what amount. There is not only no teaching of a therapeutic use, there is nothing that would lead one to estimate a dosage. Moreover, based on example 19 of Williams, the mere fact that an antibody is a neutralizing antibody (i.e., able to complex with antigen and neutralize charge so that a precipitate is formed) does not mean it will be therapeutically effective.

Queen and Engelman

Queen and Engelman were cited merely to show that humanized and/or recombinant antibodies could be made.

Queen generalizes as to the advantages of humanized antibodies over non-human antibodies. It should be noted that the advantages described therein, are generally directed to combinations of humanized light and heavy chains with donor immunoglobulin CDRs. These combinations are produced using recombinant genetic and biochemical techniques. The techniques do not incorporate the use of an intact "immune system" to produce such humanized monoclonal antibodies.

iii. *Appellants have submitted Expert Evidence which the examiner has ignored*

Although appellants do not believe the examiner has established a *prima facie* case of obviousness, in view of the faulty analysis of the references, they have submitted expert evidence to rebut the examiner's rejection. The examiner keeps saying that

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

because Krivan *claims* treatment of humans it enables and makes obvious treatment of humans, but this is contrary to the evidence submitted by appellants, which the examiner never rebuts with facts, only unsupported assertions. The declarations of experts in this field have been submitted that state that the foregoing analysis by appellants of the prior art is accurate and that Krivan neither discloses, nor makes obvious, such a formulation. The examiner has improperly ignored this evidence.

It has been well established that the examiner should consider all rebuttal arguments and evidence presented by applicants. Rebuttal evidence may include evidence of 'secondary considerations, such as 'commercial success, long felt but unsolved needs, [and] failure of others, evidence that the claimed invention yields unexpectedly improved properties or properties not present in the prior art, or evidence that the claimed invention was copied by others. It may also include evidence of the state of the art, the level of skill in the art, and the beliefs of those skilled in the art. For example, rebuttal evidence may include a showing that the prior art fails to disclose or render obvious a method for making the compound, which would preclude a conclusion of obviousness of the compound. The examiner should not evaluate rebuttal evidence for its 'knockdown' value against the prima facie case or summarily dismiss it as not compelling or insufficient. If the evidence is deemed insufficient to rebut the prima facie case of obviousness, the examiner should specifically set forth the facts and reasoning that justify this conclusion. In re Piasecki, 745 F.2d 1468 (Fed. Cir., October 17, 1984)

The evidence submitted by appellants is drawn to two areas: establishing the level of skill in the art and what the prior art teaches one of skill in the art. ... "[T]he point [is] that the legal conclusion of obviousness cannot be reached without an

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

appreciation of the level of ordinary skill in the art, *Graham v. John Deere Co.* ... and that 'level' must be determined by a consideration of all evidence made available to the trier of the issue which is related to the state of the particular technology at a given point in time. When all the evidence is evaluated, it may well turn out and often does, that the level of skill was not quite what it appeared to be when only a portion of the evidence, e.g. printed patents or publications, was considered ... "Most of the objective evidence presented by patent applicants to the Patent Office to establish nonobviousness, or, perhaps more correct in a procedural sense, to rebut a *prima facie* case of obviousness, is technical in nature--a comparison of the prior art products with the claimed products, for example. In *re Palmer*, 451 F.2d 1100, 172 USPQ 126 (CCPA 1971) "[T]his court ... has found patentable subject matter even where the invention is apparently simple in nature or quite 'close', on the surface, to the prior art, but where the small difference has eluded those of ordinary skill in the art in search of the solution to a persistent problem or where that difference unexpectedly yields an improved product or known product in an unexpectedly advantageous manner. *Id.*

The Declaration of Dr. Florian Glunzer:

Dr. Gunzer is a microbiologist in Germany, working on the virulence mechanisms of Shiga toxin producing *E. coli*. He has published in peer reviewed international journals and is an Infectious Disease consultant with the department of pediatrics at the Hanover Medical School in Germany. He has been working on a swine model for human enteric infections since 1994. This is the swine model that was crucial for applicants' discoveries leading to the claimed formulations. He has recently verified that this model develops the same disease symptoms in humans including renal thrombotic

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

microangiopathy, and concludes that it is unique in its potential for evaluating prophylactic or therapeutic approaches for HUS.

*The Declaration of Dr. John M. Leong*

Dr. John M. Leong is an Associate Professor of Molecular Genetics and Microbiology at the University of Massachusetts Medical School, a former Pew Scholar in the Biomedical Sciences and a former Established Investigator of the American Heart Association. Dr. Leong states that there are two critical features leading to life-threatening complications by Shiga toxin producing strains of *E. coli* O157:H7: (1) secretion of shiga-like toxin, which is essential for the systemic manifestations of STEC infection, and (2) generation attaching and effacing (AE) lesions on the intestinal epithelium, lesions that disrupt the cytoskeleton of epithelial cells. He then also states that the only animal model for infections with *E. coli* O157:H7 and other serotypes of STEC is the neonatal gnotobiotic piglet.

*Declaration of Dr. Saul Tzipori*

Dr. Tzipori is an inventor of this application. As he previously explained at the interview with the examiner, Dr. Tzipori spent two decades developing the pig model, to determine the virulence factors of the *E. coli* that leads to hemolytic uremic syndrome (HUS). There are two important factors that only piglets and humans have: toxin receptors on blood vessels to produce disease symptoms such as kidney failure and brain damage by the absorbed toxin. The second key factor is the ability of the bacteria to cause attaching effacing (AE) lesions (damage to the gut wall) in pigs and in humans. This facilitates the absorption of the toxin from the severely damaged gut into the blood stream. Therefore only the piglets can be used as an animal model for this human disease.

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

Moreover, only if the model has receptors on their blood vessels, and gut damaged by bacteria to facilitate absorption of the toxin, can one determine an effective dosage of the therapeutic.

Krivan does not describe a method of preventing HUS in humans. Krivan describes only the oral administration of polyclonal antibodies produced in cattle. These antibodies cannot be used to treat humans, nor is there any way to predict if they would be in the slightest way predictive of what could be done in humans.

Dr. Tzipori attaches letters from two additional experts, Dr. Harley Moom of the College of Veterinary Medicine, Iowa State University, and Dr. Phillip I. Tarr, Professor of Pediatrics and Microbiology, Washington University School of Medicine in St. Louis, that further demonstrate why the piglets are the only useful animal model and why such a model is critical to determine and characterize what an effective reagent is for treatment or prevention of HUS.

iv. *The Prior art is not enabling nor does it provide the required motivation*

As noted above, "References relied upon to support a rejection under 35 USC 103 must provide an enabling disclosure, i.e., they must place the claimed invention in the possession of the public." *Application of Payne*, 606 F.2d 303, 314, 203 U.S.P.Q. 245 (C.C.P.A. 1979); see *Beckman Instruments, Inc. v. LKB Produkter AB*, 892 F.2d 1547, 13 U.S.P.Q.2d 1301 (Fed. Cir. 1989). A publication that is insufficient as a matter of law to constitute an enabling reference may still be relied upon, but only for what it discloses. See *Reading & Bates Constr. Co. v. Baker Energy Resources Corp.*, 748 F.2d 645, 651-

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

652, 223 U.S.P.Q. 1168 (Fed. Cir. 1984); *Symbol Technologies, Inc. v. Opticon, Inc.*, 935 F.2d 1569 (Fed. Cir. 1991).

Neither Niether Krivan (bovine polyclonal antibodies) nor Williams (avian recombinant antibodies) places one of skill in the art with antibodies to STX2 which would be effective to treat or prevent HUS, and certainly not antibodies to a specific subunit of Stx2. Krivan only provides animal antibodies, and it is not clear to what toxin - it appears that it is only to the SLT forms that cause animal disease, not to the STX2 form causing HUS in humans. William is focused on antibodies produced by immunization with a fusion peptide, and there is no evidence it could protect a human from developing symptoms.

"Focusing on the obviousness of substitutions and differences, instead of on the invention as a whole, is a legally improper way to simplify the often difficult determination of obviousness." *Gillette Co. v. S.C. Johnson & Sons, Inc.*, 919 F.2d 720, 724, 16 U.S.P.Q.2d 1923 (Fed. Cir. 1990); see *Hybritech Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1383, 231 U.S.P.Q. 81, 93 (Fed. Cir. 1986). "One cannot use hindsight reconstruction to pick and choose among isolated disclosures on the prior art to deprecate the claimed invention." *In re Fine*, 837 F.2d 1071, 1075 (Fed. Cir. 1988).

Here, the examiner has taken the answer - that STX2 from certain enterohemorrhagic *E. coli* is critical to development of HUS in humans, and worked backwards to find references from which he has selected isolated phrases to support his rejection. This is clearly improper.

The prior art must provide one of ordinary skill in the art with the motivation to make the proposed modifications needed to arrive at the claimed invention. See *In re*



U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

*Geiger*, 815 F.2d 686, 2 U.S.P.Q.2d 1276 (Fed. Cir. 1987); *In re Lahu and Foulletier*, 747 F.2d 703, 705, 223 U.S.P.Q. 1257, 1258 (Fed. Cir. 1984). Claims for an invention are not *prima facie* obvious if the primary references do not suggest all elements of the claimed invention and the prior art does not suggest the modifications that would bring the primary references into conformity with the application claims. *In re Fritch*, 23 U.S.P.Q.2d, 1780 (Fed. Cir. 1992). *In re Laskowski*, 871 F.2d 115 (Fed. Cir. 1989). This is not possible when the claimed invention achieves more than what any or all of the prior art references allegedly suggest, expressly or by reasonable implication.

As is clear from the expert Declarations, those skilled in the art believe one must have used an appropriate animal model to reach the claimed invention. The prior art does not do this, in any combination. Therefore the claimed methods cannot be obvious.

The current rejections are analogous to the rejection deemed improper by the Federal Circuit. See *In re Deuel*, 34 U.S.P.Q.2d 1210 (Fed. Cir. 1995). In *Deuel*, the Court reaffirmed that a rejection based on an "obvious to try" standard was improper. The Court specifically found that prior art that teaches a method for obtaining a general result, when the actual results are unknown, is insufficient to make obvious the actual results obtained upon which the claims are based.

One of ordinary skill in the art would readily appreciate neutralization of Stx2 *in vivo* is absolutely critical to prevent or treat hemolytic uremic syndrome in a human. The prior art never describes neutralization of the toxin that prevents death and other severe symptoms, as claimed. The prior art describes neutralizing antibodies only in the classic sense - antibodies which react with antigen to form an immunoprecipitate. The applicants have provided a detailed analysis of toxin induced neurological signs and

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

bacterial lesions; and prevention and treatment of such signs and lesions in piglets. It is important to realize the advantages that are gained by using piglet model systems. Piglets require much smaller toxin doses; piglets can be infected orally with the bacteria; mice are very resistant to infection, requiring many times more toxin to become sick, than humans; cattle do not absorb toxin at all like humans. In contrast, toxin produced in the gut of piglets is taken up systemically, *just as in children*, to cause systemic complications because the piglets have receptors to which toxin binds.

There is no teaching in the cited references, singly or in combination, of an effective dosage to prevent or treat hemolytic uremic syndrome in a human, especially of an antibody to Stx2, and even less so to a single subunit of Stx2. It would not have been obvious from studies using animals such as mice what an effective dosage would be; since mice are very resistant to infection, requiring many times more toxin to become sick, much less from studies with cattle. Studies based on preincubation and injection are worthless in predicting success, only failure. The bacterial strains and therefore the toxins, as well as the hosts and the diseases, are very different. One skilled in the art cannot predict from cattle, pig and avian diseases, to treatment or prevention of human infection. Accordingly, the claimed method cannot be obvious.

v. *The examiner has failed to separately examine the dependent claims*

The examiner has "lumped" all of the claims together in his rejections, and failed to separately examine the dependent claims. These can be divided into three groups, those defining the antibodies as recombinant or humanized or chimeric antibodies, those relating to the formulation dosage, including claim 31 drawn to an effective amount to

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

treat or prevent neurological symptoms, and those to specific subunits, A or B (where A is shown to be significantly more effective than B).

The prior art does not teach administration of humanized, recombinant or chimeric antibodies. The examiner has used hindsight to say that it would be obvious to substitute humanized, recombinant or chimeric antibodies for the antibodies described by Krivan or Williams. This is not what one skilled in the art is led to by Krivan, however. Krivan teaches oral administration, not administration by injection. Krivan teaches the importance of polyclonal antibodies, not monoclonal antibodies. In summary, Krivan fails to provide any teaching of why one would want to make a recombinant or humanized antibodies, much less how one should make such antibodies or use such antibodies. Williams describes polyclonal antibodies made to a recombinant antigen, not a recombinant or humanized antibody and says it would be useful to inject a human with avian antibody. Neither Krivan nor Williams indicate there is any need to do so. One cannot use hindsight to say that even though the prior art says it is fine to use bovine or avian polyclonal antibodies for treatment, one should replace them with humanized or human monoclonal antibodies to one particular toxin, Stx2, even less so to a single subunit of Stx2. This simply found no where in the art.

The art also fails to suggest using an appropriate animal model that would lead one of skill in the art to determine an effective dosage. The art leads one instead to believe that mice and cattle are predictive of human treatment. The expert opinions submitted by appellant make it very clear this not the case.

The dosage Krivan provides is for oral administration; not parenteral (col. 10, lines 54-55). This amount, 100 mg to 5 grams, greatly exceeds the amount that would be

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF


parenterally administered to a human child. There is no dosage given in Williams. None of the secondary references make up for the deficiencies of either Krivan or Williams.

**(9) SUMMARY AND CONCLUSION**

Krivan provides is a general teaching to treat or prevent disease in calves using an oral preparation. Williams provides a recombinant peptide to immunize birds or rabbits. What is not found, however, is a method of targeting Stx2, in humans, in a dosage of antibodies to a single subunit of Stx2 that is effective to treat or prevent symptoms associated with debilitating disease or death. As the expert declarations demonstrate, those in the field did not know that one needed to target the shiga-like toxin II of the *E. coli* that infects humans, to prevent disease leading to death or kidney failure. This could not have been predicted based on data showing feeding of an immunoglobulin mixture to calves or pre-mixing toxin with antibodies and injecting it intraperitoneally into mice. Neither calves nor mice are appropriate animal models for disease in humans since the disease proceeds differently due to the lack of receptors in the rumen of the calves, and the toxins are immunologically different.

Based on the foregoing, claims 26-36 are not obvious in view of the cited art.

Respectfully submitted,



---

Patrea L. Pabst  
Reg. No. 31,284

Date: September 14, 2004  
PABST PATENT GROUP LLP  
400 Colony Square Suite 1200  
1201 W. Peachtree Street  
Atlanta, GA 30361  
(404) 879 2151  
Fax (404) 879 2160

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

**APPENDIX: Claims on Appeal**

26. (previously presented) A dosage formulation comprising an effective amount of human or humanized monoclonal antibodies, the antibodies consisting of antibodies neutralizing Shiga like toxin II *in vivo*, wherein the antibodies are specifically reactive with a single subunit of the Shiga like toxin II produced by *Escherichia coli* which causes hemolytic uremic syndrome, to prevent or treat hemolytic uremic syndrome in a human.

27. (previously presented) The dosage formulation of claim 26, wherein the antibodies are human monoclonal antibodies.

28. (previously presented) The dosage formulation of claim 26, wherein the antibodies are produced by recombinant DNA methodology.

29. (previously presented) The dosage formulation of claim 26, wherein the antibodies are chimeric monoclonal antibodies.

30. (previously presented) The dosage formulation of claim 26, wherein the antibodies bind to the alpha subunit of the Shiga like toxin II.

31. (previously presented) The dosage formulation of claim 26 wherein the antibodies are effective to prevent neurological signs of hemolytic uremic syndrome or lesions, wherein the neurological signs or lesions are selected from the group consisting of bloody diarrhea, acute renal failure, cerebral hemorrhaging, bacterial shedding into feces, bacterial lesions, paddling, head-pressing, ataxia, convulsions and wasting.

32. (previously presented) The dosage formulation of claim 26, wherein the antibodies are effective to prolong survival.

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

33. (previously presented) The dosage formulation of claim 26, wherein the antibodies bind to the beta subunit of the Shiga like toxin II.

34. (previously presented) The dosage formulation of claim 26 equivalent to 4 ml serum from an animal immunized with Shiga-like toxin II/kg body weight.

35. (previously presented) The dosage formulation of claim 26 producing a serum level of anti-Shiga toxin II antibodies of at least 0.5 micrograms/ml.

36. (previously presented) The dosage formulation of claim 26 equivalent to a dosage of 3 mg human monoclonal antibody to Shiga-like toxin II administered to a newborn pig.

U.S.S.N. 10/041,958  
Filed: January 7, 2002  
APPEAL BRIEF

## TABLE OF CONTENTS

- (1) REAL PARTY IN INTEREST
- (2) RELATED APPEALS AND INTERFERENCES
- (3) STATUS OF CLAIMS ON APPEAL
- (4) STATUS OF AMENDMENTS
- (5) SUMMARY OF THE INVENTION
- (6) ISSUES ON APPEAL
- (7) GROUPING OF CLAIMS
- (8) ARGUMENTS
  - (a) The Invention
  - (b) Rejections Under 35 U.S.C. § 103
- (9) SUMMARY AND CONCLUSION

Certificate of Mailing

Appendix: Claims On Appeal

Table of Contents

{45050708.1}